News

Article

US Patent Office Denies Amgen’s Petition to Review Humira Patents

The denial marks a setback for Amgen, who’s Humira biosimilar ABP 501 is the first submitted to FDA for adalimumab.

The US Patent and Trademark office released a statement on Jan. 14, 2016 denying Amgen’s petition to review two formulation patents for AbbVie’s Humira (adalimumab). Adalimumab is a biologic medication developed by AbbVie that is indicated for treatment of patients with rheumatoid arthritis (RA). The company currently has 70 patents protecting adalimumab with annual sales at an estimated $14 billion. In the past, the company has stated they plan on aggressively defending the patents, which they expect will protect the drug from competitors, until 2022.  

Amgen challenges multiple claims on Humira’s ‘157 patent, which focuses specifically on the antibody formulations of the drug. In the decision, the US Patent Office stated, “we find that Amgen has not established a reasonable likelihood of prevailing with respect to at least one challenged claim of the ‘157 patent.” 

The US Patent Office’s denial of the request marks a setback for Amgen, who plans to have their first biosimilar on the market between 2017 and 2019. Amgen’s biosimilar, ABP 501, is the first biosimilar submitted to FDA for Humira. According to a report by Reuters, the company says they still plan to challenge the legality of AbbVie’s patents.  

In an investor report sent on Jan. 14, 2016, Mark Schoenebaum, PhD, senior managing director of Evercore ISI's Health Care Research Team, remarks that because biosimilars do not have to have the same formulation as reference products, companies have the ability to design around formulation patents. However, he says, while these patents may not be important for all Humira biosimilars, they may be relevant for Amgen’s biosimilar. 

Source: Reuters, The United States Patent and Trademark Office 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More